Venor Pharma Limited

Venor Pharma Limited is a public limited company incorporated on May 3, 2013, in Delhi, India, with Corporate Identification Number (CIN) U74900DL2013PLC251565. The company is registered under the Registrar of Companies (RoC) Delhi. Its authorized capital is ₹5.00 crore, with a paid-up capital of ₹1.00 million. The registered office is located at A-43, Ground Floor, G.T. Karnal Road Industrial Area, Delhi, 110033.

Venor Pharma Limited specializes in the manufacturing and export of pharmaceutical finished formulations, focusing on controlled drug items, including narcotics and psychotropic substances. The company has established a significant presence in the global pharmaceutical market, exporting products across various therapeutic categories. As of March 2026, Venor Pharma Limited has a workforce of 170 employees.

Venor Pharma Limited operates a state-of-the-art manufacturing facility located in Dehradun, Uttarakhand. This facility specializes in the production of pharmaceutical finished formulations, including controlled drug medicines such as narcotics and psychotropic products. The plant is equipped with advanced technology to manufacture a diverse range of dosage forms, including sterile injectables, transdermal drug delivery systems, oral dissolving films, and oral solid dosage forms. The facility adheres to international standards and holds approvals from various regulatory bodies, ensuring compliance and quality in its manufacturing processes.

The leadership team at Venor Pharma Limited comprises several key individuals:

• Shubham Verma: Director, appointed on August 31, 2018.
• Yogesh Kapoor: Director, appointed on February 8, 2023.
• Shivam Verma: Director, appointed on May 24, 2023.
• Vishwas Verma: Director, appointed on May 3, 2013.
• Ritesh Khetarpal: Director, appointed on June 1, 2024.
• Savita Verma: Director, appointed on May 3, 2013.

These directors collectively oversee the strategic direction and operations of Venor Pharma Limited, contributing to its growth and success in the pharmaceutical industry.

Venor Pharma Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Dehradun, Uttarakhand, has been inspected and approved by various international regulatory bodies, such as the Saudi Food and Drug Authority (SFDA), Ministry of Health (MOH) UAE, Food and Drug Administration (FDA) Iraq, Sudanese National Medicines and Poisons Board (NMPB), Ethiopian Food, Medicine and Health Care Administration and Control Authority (FMHACA), Medicines Control Authority of Zimbabwe (MCAZ), Zambia Medicines Regulatory Authority (ZAMRA), Ghana Food and Drugs Authority (FDA), Tanzania Medicines and Medical Devices Authority (TMDA), Pharmacy and Poisons Board (PPB) Kenya, National Drug Authority (NDA) Uganda, and Pharmacy, Medicines and Poisons Board (PMPB) Malawi. These approvals facilitate the company's market access and distribution in these regions.

Venor Pharma Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facility holds approvals from the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification, which is essential for accessing and distributing pharmaceutical products in these regions. Additionally, the facility has received approvals from various national regulatory authorities, including the Ethiopian Food, Medicine and Health Care Administration and Control Authority (FMHACA), Medicines Control Authority of Zimbabwe (MCAZ), Zambia Medicines Regulatory Authority (ZAMRA), Ghana Food and Drugs Authority (FDA), Tanzania Medicines and Medical Devices Authority (TMDA), Pharmacy and Poisons Board (PPB) Kenya, National Drug Authority (NDA) Uganda, and Pharmacy, Medicines and Poisons Board (PMPB) Malawi. These certifications and approvals enable Venor Pharma Limited to effectively penetrate and operate in these emerging markets.

Venor Pharma Limited has adopted a diversified geographic strategy, exporting its pharmaceutical products to various regions, including Europe (non-EU), the Middle East, South America, and South Asia. This approach mitigates concentration risk and leverages growth opportunities across different markets. The company's adherence to international manufacturing standards and possession of multiple regulatory approvals underscore its commitment to quality and compliance, enhancing its strategic position in these diverse markets.

Venor Pharma Limited's manufacturing facility in Dehradun, Uttarakhand, has been inspected and approved by the U.S. Food and Drug Administration (FDA). This approval signifies the facility's compliance with FDA standards, facilitating the export of pharmaceutical products to the United States. The company's adherence to FDA regulations underscores its commitment to quality and safety in its manufacturing processes.

Venor Pharma Limited's manufacturing facility holds the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification, ensuring compliance with international manufacturing standards. Additionally, the facility aligns with European Union Good Manufacturing Practice (EU GMP) standards, further demonstrating its commitment to quality and regulatory compliance. These certifications enable the company to export its pharmaceutical products to various international markets, including those in the European Union.

Venor Pharma Limited's manufacturing facility in Dehradun, Uttarakhand, holds approvals from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority for pharmaceuticals in India. The facility has also received approvals from various state drug controllers and export No Objection Certificates (NOCs), facilitating the export of pharmaceutical products from India to international markets. These regulatory approvals ensure that the company's products meet the required standards for safety, efficacy, and quality.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Venor Pharma Limited by regulatory authorities. This absence suggests that the company maintains a strong compliance record with regulatory standards.

Venor Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on controlled drug items, including narcotics and psychotropic substances, positions it uniquely in the market. Its adherence to international manufacturing standards and possession of multiple regulatory approvals provide a competitive edge, enabling access to various global markets. However, the company faces competition from both domestic and international manufacturers in the controlled substances segment.

Venor Pharma Limited's key differentiators include its specialization in controlled drug items, adherence to international manufacturing standards, and possession of multiple regulatory approvals. The company's manufacturing facility's certifications, such as WHO-GMP and EU GMP, underscore its commitment to quality and compliance. These factors enable Venor Pharma Limited to effectively serve diverse international markets, including Europe, the Middle East, South America, and South Asia.

Venor Pharma Limited's current strategic direction focuses on the manufacturing and export of pharmaceutical finished formulations, particularly controlled drug items. The company's adherence to international manufacturing standards and possession of multiple regulatory approvals position it favorably in the global pharmaceutical market. Looking ahead, Venor Pharma Limited aims to expand its market presence by leveraging its manufacturing capabilities and regulatory compliance to access new markets and strengthen its position in existing ones.

Venor Pharma Limited has demonstrated a consistent track record in the pharmaceutical industry, with a total export value of $8.6 million USD and 497 shipments across nine products in four therapeutic categories. The company's portfolio concentration, with the top five products accounting for 94.7% of exports, indicates a focused approach to its product offerings. The absence of publicly available records indicating regulatory issues further underscores the company's reliability as a supplier.

Importers should verify the following certifications when considering Venor Pharma Limited as a supplier:

• FDA Approval: Confirm the facility's registration and compliance with FDA standards.
• WHO-GMP Certification: Ensure the manufacturing facility holds WHO-GMP certification.
• EU GMP Certification: Verify the facility's compliance with EU GMP standards.